Corcept Therapeutics Incorporated (NASDAQ:CORT) said on Thursday that it presented results from its Phase 2 DAZALS study of ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Experimental drug Ulefnersen offers hope for rare, early-onset Amyotrophic lateral sclerosis (ALS) in clinical trials.

Prescribed use of anti-anxiety drugs, hypnotics and sedatives, or antidepressants was tied to a higher future risk of ...

UC Irvine researchers conducted a study to better understand the molecular basis of amyotrophic lateral sclerosis (ALS), a ...

Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering ...

Brainstorm tapped Minaris to manufacture NurOwn for its upcoming Phase 3b clinical trial testing the treatment for ALS.

Dr. Simrit Parmar, an associate professor in the College of Medicine at Texas A&M University and founder of the ...

Corcept Therapeutics' dazucorilant failed the primary ALS trial goal but showed improved survival outcomes and a safe profile ...

The donation will establish the Lois Pope Neuroscience Research Fund and will add Lorraine's name to the Lois Pope Laboratory ...

Amyotrophic lateral sclerosis (ALS) is a progressive disease that causes severe weakness due to progressive degeneration of a specific set of motor nerves in the spinal cord. People with ALS will ...